SCHEMBL481577

SCHEMBL481577

Nc1ncc(CC2CCOC2)nc1N

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 1/20 0.39
XDH P47989 1/20 0.34
PIK3CD O00329 6/20 0.34
PIK3CB P42338 6/20 0.34
PIK3CG P48736 5/20 0.34
TLR7 Q9NYK1 4/20 0.33
DHFR P00374 1/20 0.33
DCPS Q96C86 1/20 0.33
MTOR P42345 2/20 0.33
CYP11B2 P19099 1/20 0.33
PIK3CA P42336 2/20 0.32
PIK3R1 P27986 1/20 0.32
MAP4K4 O95819 1/20 0.32
AKT1 P31749 1/20 0.32
ADORA2A P29274 2/20 0.32
ADORA2B P29275 2/20 0.32
ADORA1 P30542 2/20 0.32
NLRP3 Q96P20 1/20 0.32
GRM4 Q14833 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL481935 0.90 CYP11B2 (0.40) MCHR1PIK3CDPIK3CBPIK3CGTLR7
SCHEMBL481595 0.78 DAO (0.36) MCHR1PIK3CDPIK3CBPIK3CGTLR7
SCHEMBL482011 0.77 CYP11B2 (0.41) MCHR1MTORCYP11B2
SCHEMBL31403581 0.74 MCHR1 (0.40) MCHR1XDHDHFRDCPSMTOR
SCHEMBL2143997 0.72 MCHR1 (0.50) MCHR1DHFRDCPS
SCHEMBL481911 0.71 MAP4K4 (0.33) PIK3CAPIK3R1MAP4K4
SCHEMBL29313468 0.71 CYP11B2 (0.32) CYP11B2
SCHEMBL481912 0.71 MAP4K4 (0.33) PIK3CAPIK3R1MAP4K4
SCHEMBL17221743 0.69 GBA1 (0.37) MCHR1XDHADORA2AADORA2BADORA1
SCHEMBL30856772 0.69 GBA1 (0.37) MCHR1XDHADORA2AADORA2BADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2457913-A2 Heteroaryl compounds, compositions thereof, and methods of treatment therewith Signal Pharmaceuticals LLC (US) 2012-05-30 EP disclosed
EP-2078016-B1 HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH SIGNAL PHARM LLC (US) 2012-02-01 EP disclosed
US-20110245245-A1 METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS SIGNAL PHARMACEUTICALS, LLC 2011-10-06 US disclosed
US-7981893-B2 Heteroaryl compounds, compositions thereof, and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC (US) 2011-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245245-A1 METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS JAK2, GLS2, NFKBIA MCHR1 4206/4885XDH 391/4885PIK3CD 1352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.